XML 28 R8.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
9 Months Ended
Sep. 28, 2019
Sep. 29, 2018
Cash Flows From (For) Operating Activities    
Net income $ 165.1 $ 49.6
Adjustments to derive cash flows:    
Depreciation and amortization 293.5 324.0
Gain on sale of business (72.4)  
Share-based compensation 40.9 26.6
Impairment charges 42.9 223.5
Change in financial assets (18.5) (65.9)
Restructuring charges 26.7 23.2
Deferred income taxes 10.1 (8.4)
Amortization of debt premium (3.8) (6.2)
Other non-cash adjustments, net 38.5 6.4
Subtotal 523.0 572.8
Increase (decrease) in cash due to:    
Accounts receivable (12.1) 20.2
Inventories (78.3) (101.3)
Accounts payable 33.7 44.5
Payroll and related taxes (10.6) (40.8)
Accrued customer programs (82.7) (1.2)
Accrued liabilities (24.8) (31.1)
Accrued income taxes (65.8) (60.0)
Other, net 15.9 (4.4)
Subtotal (224.7) (174.1)
Net cash from (for) operating activities 298.3 398.7
Cash Flows From (For) Investing Activities    
Proceeds from royalty rights 2.2 11.4
Purchase of investment securities   (7.5)
Acquisitions of businesses, net of cash acquired (749.5)  
Proceeds from the Royalty Pharma contingent milestone 250.0  
Asset acquisitions (86.2) (32.8)
Additions to property, plant and equipment (90.3) (56.8)
Net proceeds from sale of business 183.4 0.0
Other investing, net 0.6 5.0
Net cash from (for) investing activities (489.8) (80.7)
Cash Flows From (For) Financing Activities    
Issuances of long-term debt 600.0 431.0
Payments on long-term debt (476.0) (470.0)
Borrowings (repayments) of revolving credit agreements and other financing, net 0.8 (8.7)
Deferred financing fees (1.0) (2.4)
Issuance of ordinary shares 0.7 1.0
Repurchase of ordinary shares   (400.0)
Cash dividends (83.6) (78.7)
Other financing, net (7.6) (9.8)
Net cash from (for) financing activities 33.3 (537.6)
Effect of exchange rate changes on cash and cash equivalents 5.6 (14.9)
Net increase (decrease) in cash and cash equivalents (152.6) (234.5)
Cash and cash equivalents, beginning of period 551.1 678.7
Cash and cash equivalents, end of period $ 398.5 $ 444.2